Drug intelligence / Profile preview

RJx-02 + RJx-06

Development stage: Preclinical
Lead developer: Rejuvenate Biomed
Modality: Small Molecules

Overview

RJx-02 + RJx-06 is a combination drug candidate currently in the discovery phase of development by Rejuvenate Biomed. The program was identified using the company's proprietary AI-driven platform, which focuses on discovering synergistic combinations of existing small molecules to target biological pathways associated with aging and age-related diseases. While the specific molecular targets and the primary therapeutic indication remain undisclosed, the candidate follows the company's strategy of repurposing known compounds to create novel, proprietary therapies with enhanced efficacy and safety profiles.

Beyond the preview

Go deeper on RJx-02 + RJx-06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RJx-02 + RJx-06.

Explore the full profile